Next-generation PERG devices and methods
下一代PERG设备和方法
基本信息
- 批准号:8779609
- 负责人:
- 金额:$ 15.5万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2014
- 资助国家:美国
- 起止时间:2014-09-01 至 2016-08-31
- 项目状态:已结题
- 来源:
- 关键词:AccountingAdoptionAdvanced DevelopmentAmplifiersAnimal ModelAnimalsBiomedical EngineeringBlindnessCell DeathCell physiologyCessation of lifeClinicalCommunitiesComputer softwareCoupledData AnalysesDependencyDetectionDevelopmentDevicesDiagnosticDimensionsDiseaseEarly DiagnosisElectroretinographyExhibitsExperimental ModelsEyeFunctional disorderGlaucomaGoalsGogglesHeadHealthHumanInfluentialsLaboratory miceLeadLeftLightMeasurementMeasuresMethodsMonitorMusNoisePatientsPatternPerformancePharmacologic SubstancePhasePhysiologic Intraocular PressurePositioning AttributePosturePublic HealthPupilResearchRetinal DegenerationRetinal DiseasesRetinal Ganglion CellsRodentScientistSignal TransductionStagingStimulusSystemTechniquesTechnologyTestingTherapeuticTimeTwin Multiple BirthUncertaintyVisionVision researchWorkanimal model developmentbaseclinical applicationcostdesigndigitalfunctional losshuman subjectimprovedin vivoinnovationlaptopmouse modelnext generationnoveloptic nerve disorderpreventprototypepublic health relevanceresponsescreeningtooluser-friendly
项目摘要
DESCRIPTION (provided by applicant): Glaucoma is one of a number of optic nerve diseases which lead to retinal ganglion cells (RGC) degeneration, ultimately manifesting in a functional loss of vision if left untreated. There exist a number of therapeutic approaches to treat these conditions, but there are currently no clinical methods to detect the onset of RGC dysfunction. The Pattern Electroretinogram (PERG) is the only established tool to monitor RGC health in vivo in humans and experimental models of optic nerve diseases. The monitoring of PERG responses can potentially provide earlier detection of degenerative retinal disorders such as glaucoma, allowing for treatment paradigms to be initiated before irreversible functional vision loss has occurred. A critical barrier to the widespread adoption of PERG for research and clinical use is the lack of availability of an easy-to-use, turnkey device for recording and data analysis. The goal of the proposed project is to produce commercially available devices for use in both vision research and clinical applications, which are more compact, faster, cheaper and more user-friendly. During Phase I, the following specific aims will pursued: 1) Development of a hardware platform containing a digital signal processor and the necessary amplifiers to interface with the next-generation PERG stimulators. 2) Development of a lightweight LED-based PERG stimulator for animal studies. 3) Development of a lightweight AMOLED-based goggle PERG stimulator for humans. 4) Development of advanced stimulation sequences which will reduce spurious cross talk components. The performance of the prototype devices will be evaluated and optimized. Successful completion of our research will provide allow large community of clinicians and scientists to more easily take advantage of the PERG technique.
描述(由申请人提供):青光眼是导致视网膜神经节细胞(RGC)变性的众多视神经疾病之一,如果不及时治疗,最终表现为视力功能丧失。有许多治疗方法可以治疗这些疾病,但目前还没有临床方法来检测RGC功能障碍的发病。视网膜电图(PERG)是唯一一种用于监测RGC在人体和视神经疾病实验模型中的健康状况的工具。监测PERG反应可以潜在地提供退行性视网膜疾病(如青光眼)的早期检测,允许在发生不可逆的功能性视力丧失之前启动治疗模式。在研究和临床应用中广泛采用PERG的一个关键障碍是缺乏易于使用的记录和数据分析交钥匙设备。这个项目的目标是生产商业上可用的设备,用于视觉研究和临床应用,这些设备更紧凑、更快、更便宜、更方便用户。在第一阶段,将追求以下具体目标:1)开发一个包含数字信号处理器和必要放大器的硬件平台,以与下一代PERG刺激器接口。2)开发用于动物实验的轻型led PERG刺激器。3)基于amoled的轻型人体护目镜PERG刺激器的研制。4)开发先进的刺激序列,减少杂散串扰分量。将对原型器件的性能进行评估和优化。我们的研究的成功完成将使大量的临床医生和科学家能够更容易地利用PERG技术。
项目成果
期刊论文数量(2)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Jonathon Anthony Toft-Nielsen其他文献
Jonathon Anthony Toft-Nielsen的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Jonathon Anthony Toft-Nielsen', 18)}}的其他基金
Advanced CLAD PERG system with minimal patient preparation for clinical settings (Phase II)
先进的 CLAD PERG 系统,只需最少的患者准备即可进行临床设置(第二阶段)
- 批准号:
10698852 - 财政年份:2019
- 资助金额:
$ 15.5万 - 项目类别:
相似海外基金
Investigating the Adoption, Actual Usage, and Outcomes of Enterprise Collaboration Systems in Remote Work Settings.
调查远程工作环境中企业协作系统的采用、实际使用和结果。
- 批准号:
24K16436 - 财政年份:2024
- 资助金额:
$ 15.5万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
WELL-CALF: optimising accuracy for commercial adoption
WELL-CALF:优化商业采用的准确性
- 批准号:
10093543 - 财政年份:2024
- 资助金额:
$ 15.5万 - 项目类别:
Collaborative R&D
Unraveling the Dynamics of International Accounting: Exploring the Impact of IFRS Adoption on Firms' Financial Reporting and Business Strategies
揭示国际会计的动态:探索采用 IFRS 对公司财务报告和业务战略的影响
- 批准号:
24K16488 - 财政年份:2024
- 资助金额:
$ 15.5万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 15.5万 - 项目类别:
EU-Funded
Assessing the Coordination of Electric Vehicle Adoption on Urban Energy Transition: A Geospatial Machine Learning Framework
评估电动汽车采用对城市能源转型的协调:地理空间机器学习框架
- 批准号:
24K20973 - 财政年份:2024
- 资助金额:
$ 15.5万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 15.5万 - 项目类别:
EU-Funded
De-Adoption Beta-Blockers in patients with stable ischemic heart disease without REduced LV ejection fraction, ongoing Ischemia, or Arrhythmias: a randomized Trial with blinded Endpoints (ABbreviate)
在没有左心室射血分数降低、持续性缺血或心律失常的稳定型缺血性心脏病患者中停用β受体阻滞剂:一项盲法终点随机试验(ABbreviate)
- 批准号:
481560 - 财政年份:2023
- 资助金额:
$ 15.5万 - 项目类别:
Operating Grants
Our focus for this project is accelerating the development and adoption of resource efficient solutions like fashion rental through technological advancement, addressing longer in use and reuse
我们该项目的重点是通过技术进步加快时装租赁等资源高效解决方案的开发和采用,解决更长的使用和重复使用问题
- 批准号:
10075502 - 财政年份:2023
- 资助金额:
$ 15.5万 - 项目类别:
Grant for R&D
Engage2innovate – Enhancing security solution design, adoption and impact through effective engagement and social innovation (E2i)
Engage2innovate — 通过有效参与和社会创新增强安全解决方案的设计、采用和影响 (E2i)
- 批准号:
10089082 - 财政年份:2023
- 资助金额:
$ 15.5万 - 项目类别:
EU-Funded
Collaborative Research: SCIPE: CyberInfrastructure Professionals InnoVating and brOadening the adoption of advanced Technologies (CI PIVOT)
合作研究:SCIPE:网络基础设施专业人员创新和扩大先进技术的采用 (CI PIVOT)
- 批准号:
2321091 - 财政年份:2023
- 资助金额:
$ 15.5万 - 项目类别:
Standard Grant














{{item.name}}会员




